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ABSTRACT
The tumour microenvironment (TME) is an important factor in determining 
the growth and metastasis of colorectal cancer, and can aid tumours by both 
establishing an immunosuppressive milieu, allowing the tumour avoid immune 
clearance, and by hampering the efficacy of various therapeutic regimens. The 
tumour microenvironment is composed of many cell types including tumour, stromal, 
endothelial and immune cell populations. It is widely accepted that cells present in 
the TME acquire distinct functional phenotypes that promote tumorigenesis. One 
such cell type is the mesenchymal stromal cell (MSC). Evidence suggests that MSCs 
exert effects in the colorectal tumour microenvironment including the promotion 
of angiogenesis, invasion and metastasis. MSCs immunomodulatory capacity may 
represent another largely unexplored central feature of MSCs tumour promoting 
capacity. There is considerable evidence to suggest that MSCs and their secreted 
factors can influence the innate and adaptive immune responses. MSC-immune cell 
interactions can skew the proliferation and functional activity of T-cells, dendritic 
cells, natural killer cells and macrophages, which could favour tumour growth and 
enable tumours to evade immune cell clearance. A better understanding of the 
interactions between the malignant cancer cell and stromal components of the TME 
is key to the development of more specific and efficacious therapies for colorectal 
cancer. Here, we review and explore MSC- mediated mechanisms of suppressing 
anti-tumour immune responses in the colon tumour microenvironment. Elucidation 
of the precise mechanism of immunomodulation exerted by tumour-educated MSCs 
is critical to inhibiting immunosuppression and immune evasion established by the 
TME, thus providing an opportunity for targeted and efficacious immunotherapy for 
colorectal cancer growth and metastasis.
INTRODUCTION
Worldwide colorectal cancer (CRC) is the third 
most common cancer diagnosed in men, and the second 
most common in women [1]. In 2014 in the US alone, an 
estimated 130,000 people were diagnosed with colorectal 
cancer, with 50,000 deaths from the disease [2]. Colorectal 
cancer develops slowly, beginning with adenoma and 
progressing over several years to carcinoma [3]. Although 
the stages of colorectal cancer may be defined [4], the 
origins of the disease are numerous and multifactorial. 
Microsatellite instability is detected in about 15% of CRC 
cases, meaning that these tumours have defective DNA 
mismatch repair. It is thought that these tumours are more 
immunogenic than their microsatellite stable counterparts 
due to the generation of large numbers of abnormal 
peptides [5]. As such, the tumours are characterised by a 
larger lymphocyte infiltrate and better prognosis for the 
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patient [5, 6]. In many cases, colon cancer is diagnosed 
as localised disease, however, the majority of deaths in 
CRC are due to the development of therapy refractory 
metastatic disease. Tumour growth and metastasis are 
promoted by factors in the vicinity of the tumour, known 
as the tumour microenvironment. The “seed and soil” 
hypothesis proposed as far back as 1889 by Stephen Paget 
when he noticed that a cancer cell (the “seed”) would 
only grow if the environment (the “soil”) was suitable 
[7]. It is now widely accepted that the microenvironment 
within which a tumour grows is critical to its survival and 
progression [8]. 
The colon tumour microenvironment (TME) is 
composed of many cell types including endothelial cells, 
immune cells and fibroblasts [9-12]. These constituents 
influence the survival and growth of the tumour through 
secretion of factors necessary for angiogenesis, aiding 
tumour cells in evading apoptosis, or enabling tumours 
to evade the immune system detection and elimination 
[10, 13, 14]. More recently, a newer accomplice to the 
crime has been identified - the mesenchymal stromal cell 
(MSC). As described recently by Owens, et al, the stromal 
cell niche in the intestine is comprised of numerous, 
heterogenous subsets of stromal cells, defined as CD45- 
Epcam- cells, and includes fibroblasts, myofibroblasts, and 
MSCs [15]. In healthy intestine, subsets of stromal cells 
have been defined by their expression of α-SMA, FAPα+, 
CD90+, ICAM-1+ and gp38+ (Podoplanin). Stromal cells 
in the intestine can display capacity to sense, initiate 
and respond to extrinsic immunological ques, including 
pathogens and inflammation [15]. In fitting with their 
proposed immunological functions, stromal cells are 
located close to blood vessels and the lymphatic network 
and are positioned adjacent to the intestinal epithelial 
cancer cells. Both the high proportion and localisation 
of stromal cells in the colon suggest that the function of 
these cells is likely crucial to intestinal homeostasis and 
cancer. In this article, we review current knowledge of 
stromal, tumour and immune cell interactions in colon 
tumours, with a focus on new data that has increased our 
understanding of the immunological consequences of 
stromal cell interactions and how they may be manipulated 
in the context of colorectal cancer.
MESENCHYMAL STROMAL CELLS 
(MSCs) AND CANCER-ASSOCIATED 
FIBROBLASTS (CAFs) - ONE AND THE 
SAME?
Mesenchymal stromal cells (MSCs) are non-
haematopoietic multipotent adult stromal cells which 
display a fibroblast-like morphology. MSC reside in the 
bone marrow, but are also found in tissues such as adipose 
tissue, umbilical cord blood, and dental pulp [16-18], and 
support homeostasis in healthy tissue during regeneration 
and wound healing. MSCs are defined ex vivo by the 
following basal cell surface protein expression: CD45- 
CD31- CD34- CD14- CD11b- DC79α- CD19- MHC-I low 
MHC-II low and CD105+, CD90+ and CD73+, as well as 
their ability of tri-lineage differentiation capacity i.e. 
differentiation to osteoblasts, adipocytes or chondrocytes 
[19]. While MSCs from other species share the 
characteristics of tissue culture plastic adherence and tri-
lineage differentiation, their cell surface characterisation 
is more complex and varies greatly between species. For 
example, Peister et al., found mouse MSCs to express 
varying levels of CD34 and stem cell antigen-1 (Sca-1) 
[20].
MSCs have potent immunomodulatory capacity 
and are being investigated as a cellular therapy for use 
in a broad range of inflammatory diseases, including 
osteoarthritis, graft-versus-host disease (GvHD), and 
myocardial infarction (MI) [21]. Characteristics that 
make MSCs attractive as an immunomodulatory therapy 
include their ability to home to the sites of inflammation 
and injury and release growth factors or cytokines, to 
promote healing [22, 23], to dampen inflammation [24] 
or to differentiate into various types of damaged tissues 
[25]. The anti-inflammatory properties of MSCs are 
dependent on the ability of MSCs to respond to their 
environment and become “activated”. Pro-inflammatory 
stimuli, including TNF-α, IL-1β, IL-6 or IFN-γ can 
enhance the immunosuppressive capabilities of MSCs 
[26, 27]. This enhanced immunosuppressive ability 
in response to inflammation is obviously attractive 
in diseases such as GvHD or MI. In the context of the 
tumour microenvironment, however, in the presence of 
a high level of pro-inflammatory signalling, these potent 
immunomodulatory properties can potentially influence 
the anti-tumour immune response and angiogenesis [28].
The stromal cell compartment of the tumour 
microenvironment has recently been shown to have 
important prognostic and diagnostic relevance to patient 
outcomes in colon cancer. The stromal cell compartment 
includes cancer associated fibroblasts (CAF), myo-
fibroblasts, myeloid cells, endothelial cells and MSCs [8]. 
Recently, it has been proposed that MSCs are precursors 
to cancer-associated fibroblasts, and the two cells types 
have been shown to express similar cell surface markers 
[29-31]. (Figure 1). Fibroblasts are a population of 
non-vascular, non-epithelial, non-inflammatory cells 
that form part of and help synthesise connective tissue 
[13] They are known to play an active role in wound 
healing, and the activated fibroblasts found in the tumour 
microenvironment (CAFs) are believed to be of a similar 
“wound-heal-promoting” phenotype [13] .Like MSCs, 
CAFs originate in the bone marrow [29, 32, 33]. In 
terms of cell surface marker expression, there are many 
similarities between MSCs and CAFs. MSCs present in 
tumours have been found to express fibroblast-activating 
protein (FAP) and fibroblast-specific protein (FSP), CAF-
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Table 1: Outline of studies using specific cellular markers to define the role of stromal cells in colon cancer
Study Cancer type
Source of 
fibroblasts/ 
CAFs
CAF marker(s) Effect on tumour Effect on immune response
Nakagawa
[40]
Metastatic colon 
cancer
Fibroblasts 
isolated from 
3patients 
with liver 
metastasis
Lack of epithelium specific 
markers cytokeratin-19 and 
-20. Positive for vimentin 
(RT-PCR) and α-SMA 
(immunofluorescence)
Increased HCT116 proliferation in 
vivo Not assessed
Nagasaki
[41] Colon cancer
Fibroblasts 
isolated from 
64 year old 
patient
Lack of cytokeratin, 
positive for CD90 
and vimentin 
(immunostaining) α-SMA 
(immunofluorescence)
Blocking stromal IL-6 decreased 
tumour growth and angiogenesis in 
mouse xenograft model
Not assessed
Zhang
[42]
Epithelial 
Ovarian 
Carcinoma 
(EOC)
Fibroblasts 
isolated from 
61 patients 
with EOC
Negative for 
cytokeratin-8, positive 
for FAP and vimentin 
(immunohistochemistry)
Increased α-SMA staining in 
advanced disease and in cases 
with lymph node and omentum 
metastasis.
Positive correlation between α-SMA 
and lymphatic and microvessel 
densities
In vitro fibroblasts promoted 
invasion and migration of ovarian 
cancer
Not assessed
Olumi
[44] Prostate cancer
CAFs from 
3 prostate 
cancer 
patients
Negative for cytokeratin 
and positive for 
α-SMA and vimentin 
(immunofluorescence)
CAFs promoted tumour progression 
when grafted as tissue recombinants 
into nude mice. Tissue recombinants 
+ CAFs appeared metastatic, 
recombinants + normal fibroblasts 
appeared benign
Not assessed
Direkze
[33]
Pancreatic 
insulinoma
Fibroblasts 
isolated from 
mouse bone 
marrow
α-SMA for myofibroblasts 
vimentin for fibroblasts 
(immunostaining)
RIPTag mice administered GFP+ 
bone marrow via tail vain following 
whole body irradiation. In 
pancreatic tumours that developed, 
25% of myofibroblats found to be 
bone marrow derived
Not assessed
Mishra
[29] Breast Cancer
In vitro 
expansion 
of human 
bone marrow 
MSCs. 
α-SMA, vimentin, FSA 
(immunofluorescence)
Tumour-conditioned MSCs co-
cultured with tumour cell line 
increased tumour cell growth and 
proliferation
Not assessed
Spaeth
[31] Ovarian cancer
Human bone 
marrow 
MSCs
FSP, FAP, tenascin-c, 
thrombospondin-1, 
stromelysin-1, α-SMA, 
desmin, VEGF 
(immunohistochemistry)
Co-injection of MSCs with tumour 
cells resulted in significantly larger 
tumours
Not assessed
Erez
[34]
Squamous skin 
carcinoma
CAFs isolated 
from mouse 
dysplastic 
skin
PDGFR- α (flow 
cytometry)
Tumours co-injected with CAFs 
demonstrated enhanced growth and 
vascularisation
Co-injection of 
CAFs resulted in 
increased recruitment 
of macrophages 
which supported 
increased tumour 
vascularisation
Shainagawa
[46] Colon cancer
Human bone 
marrow 
MSCs 
expanded in 
vitro
α-SMA, PDGFR-β, 
desmin, FSP, FAP 
(Immunofluorescence)
Tail vein injection of MSCs into 
tumour bearing mice. MSCs 
detected in primary tumour site and 
liver metastasis. 
Co-injection of MSCs and tumour 
cells resulted in enhanced tumour 
growth, increased PCNA-LI, 
increased MVA and decreased AI
Not assessed
Koliaraki
[37] Colon cancer
Intestinal 
tissue
CD45, Ter119, CD31 
E-cadherin negative, CD29, 
CD44, CD104- α positive 
(Flow cytometry). α-SMA, 
vimentin, collagen IV 
(immunohistochemistry)
Vimentin, collagen IV 
(flow  cytometry)
Deletion of Ikkβ in intestinal 
mesenchymal cells protected 
against inflammation associated 
carcinogenesis
Ikkβ in intestinal 
mesenchymal cells 
regulated immune 
cell infiltrate and 
cytokine production
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defining markers [31]. Additionally, platelet derived 
growth factor receptor-alpha (PDGFR)-α has been 
used to identify CAFs, based on reports demonstrating 
PDGFR-α expression on up to 90% of stromal fibroblasts 
in solid tumours [34, 35]. This marker however, is not 
unique to fibroblasts, and is commonly used to purify 
murine bone marrow-derived MSCs [36]. The lack of 
knowledge regarding specific cell surface molecules or 
cell specific promoters associated with different cell types 
of mesenchymal origin, including MSCs and CAFs in the 
tumour stroma, is a major limitation in progressing our 
understanding of their individual functions in the TME.
In fact, the lack of cell specific markers or cell 
specific promoters has led to conflicting results in models 
of colitis associated cancer. To elucidate the role of IKKβ 
signalling in “intestinal mesenchymal cells” or “CAFs” 
one study found IKKβ in these cells to be tumour-
promoting, the second found it to be anti-tumorigenic 
[37, 38] . The major difference between these two studies 
was the use of two different Cre drivers to target the 
cell in which to delete IKKβ - ColVCre where tumour 
progression was seen and Col1a2Cre-ER where an anti-
tumour effect was observed. In fact many of the markers 
used to define MSCs, e.g. FSP1 (S100A4) are also 
expressed by macrophages in the stromal compartment 
of tumours [39]. The lack of specificity in cell surface 
markers used to ascribe different populations of stromal 
cells in the TME has led to much disparity in assigning 
cellular functions to unique stromal cell populations. The 
disparity in these studies highlights the heterogeneity 
that exists in an environment like the intestine and 
demonstrates the critical importance of defining cellular 
markers or cell specific promoters that will allow us to 
confidently identify and target different stromal cell 
populations in the TME.
As well as sharing cell surface markers with MSCs, 
CAFs have also been shown to have tumour promoting 
properties in the TME (Table 1). CAFs have been shown 
to influence the growth and progression of tumours [30, 
40-42]. Activated fibroblasts, or myofibroblasts - identified 
by their expression of α-smooth muscle actin (α-SMA) - 
are important forces driving tumour progression not least 
in the case of colorectal cancer [43, 44]. Conditioned 
medium from CAFs isolated from patients with metastatic 
colon cancer promote colon cancer cell proliferation 
to a greater extent compared to normal fibroblasts from 
the same organ [40]. MSCs exposed to the conditioned 
medium from tumours have also been found to exhibit a 
similar gene expression profile to CAFs [29, 31, 45, 46]. 
In colorectal cancer, the same effect has been observed 
i.e. that MSCs injected with CRC cells expressed CAF-
defining markers via TGF-β/SMAD signalling and 
promoted tumour growth [45, 46]. 
A recent review by Madar et al., put forward the 
notion that “CAF” is a cell “state” rather than a cell 
type [47], and this fits with the hypothesis that MSCs 
are CAF-precursors. MSCs are a highly plastic cell type 
with robust differentiation capacity, are recruited to sites 
of inflammation and have a functional phenotype that is 
differentially regulated by inflammatory cytokines [48]. 
Furthermore, Calon et al. found TGF-β levels to be a 
robust predictor of disease relapse in a cohort of 345 CRC 
patients. This was an interesting finding in light of studies 
identifying TGF-β as an important factor in causing the 
Pallangyo
[38] Colon cancer
Intestinal 
tissue
PDGFRα, CD29, CD44 
positive, PDGFRβ CD45, 
Ter119, CD31 EpCAM 
negative (flow cytometry)
Vimentin, FSP, α-SMA 
(immunofluorescence)
Lack of Ikkβ in intestinal fibroblasts 
increases tumour size Not assessed
Kraman 
[51]
Lewis lung 
carcinoma and 
pancreatic ductal 
adenocarcinoma
Mouse 
tumour tissue
FAP, α-SMA, Col I 
(Immunostaining)
LLC – depletion 
of FAP+ cells 
induced necrosis 
of tumour cells. 
PDA – depletion of 
FAP+ cells allowed 
immunogenic control 
of tumour growth
Feig
[52]
Pancreatic ductal 
adenocarcinoma
Mouse 
tumour tissue
FAP, α-SMA 
(Immunostaining) PDGFR- 
α positive, CD45 negative 
(Flow cytometry)
Inhibiting CXCR4, 
a receptor for 
FAP+ stromal cell 
CXCL12 promoted 
T cell accumulation 
and synergised 
with checkpoint 
antagonists resulting 
in tumour regression
Calon
[49] Colon cancer
Human colon 
adenoma and 
carcinoma 
tissue
FAP
Pharmacological inhibition of 
stromal cell TGF-β signalling 
blocked initiation of metastasis
Not assessed
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differentiation of MSCs to a CAF-like phenotype [49]. 
They also engineered CRC cell lines, which display a 
mutational inactivation of the TGF-β pathway, to secrete 
active TGF-β1. When injected in vivo these cells increased 
tumour formation compared with controls, and since the 
tumour cells were insensitive to TGF-β signalling, they 
concluded that the observed effects were due to TGF-β 
influencing stromal cells [49]. 
MSCs also have potent immunosuppressive 
capabilities and data shows that this property is maintained 
even as mesenchymal cells differentiate [50]. CAFs, the 
product of tumour-induced MSC differentiation, have 
been found to be similarly immunosuppressive. Kraman 
et al., found that depleting fibroblast-activating protein-α 
(FAP)+ cells in a murine model caused hypoxic necrosis 
and decreased tumour volumes [51]. This could be 
reversed by anti-TNF-α or anti-IFN-γ therapy, suggesting 
that FAP+ cells attenuate cellular responses to these 
cytokines, thus protecting the tumour from cytokine-
induced clearance. Similarly, Feig et al., observed reduced 
tumour growth upon depletion of CAFs (FAP+ cells) from 
a model of pancreatic ductal adenocarcinoma (PDA), but 
interestingly only in the presence of CD4 and CD8 cells 
[52]. This effect was mimicked by administration of an 
inhibitor of CXCR4, the ligand for which, CXCL12, is 
present in CAFs and was suggested as being responsible 
for the tumour promoting effects of the CAFs. A rapid 
accumulation of T-cells in the tumour was observed 
when CXCR4 was inhibited, thus restoring the ability of 
the immune system to eliminate the cancer cells. These 
Figure 1: Outline of potential progenitor cells for cancer associated fibroblasts in the tumour microenvironment. Adapted 
from Cirri et al., (33). Cancer-associated fibroblasts (CAFs) represent major and important component of the tumour microenvironment 
(TME) and have been shown to affect tumour growth and progression. It has been suggested that these CAFs can differentiate from 
numerous cellular progenitors including tumour-resident fibroblasts, endothelial cells, epithelial cells and smooth muscle cells. However, it 
has more recently been noted that CAFs share a number of characteristics with mesenchymal stromal cells (MSCs) including the expression 
of platelet derived growth receptor (PDGFR)-α, and, upon isolation from a tumour MSCs have been shown to express fibroblast-activating 
protein (FAP) and fibroblast-specific protein (FSP) the reported hallmarks of CAFs. Furthermore, it has been suggested that “CAF” is a cell 
“state” rather than a specific cell type, pointing to a precursor with a plastic phenotype and robust differentiation capacity, typical of MSCs, 
For these reasons it has now been hypothesised that MSCs, along with their capacity to differentiate into pericytes, are also the precursors 
of CAFs in the TME.
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findings highlight the fact that a better understanding of 
the precise interactions between tumour cells, stromal 
cells and immune cell populations that regulate immune 
responses will enable new strategies for enhancing anti-
tumour immunity. 
While the limitations in defining exclusive cellular 
populations of mesenchymal origin has important 
implications in targeting these defined cell type’s in 
vivo, identification of common mechanisms of tumour 
promotion or immune modulation may represent an 
alternative approach to understanding their individual 
cellular functions in the TME. In fact, identification of 
signalling pathways activated in MSCs in response to 
inflammatory stimuli which lead to potentiation of their 
immunosuppressive capacity or even their differentiation 
to a CAF-like lineage could prove essential for therapeutic 
targeting approaches. To date, however, limited data 
exists that propose common signalling pathways that 
may be relevant to stromal cell immunomodulatory 
potential in tumours. A limited number of studies have 
attempted to address this question particularly in relation 
to harnessing the immunosuppressive potential of MSCs 
for cellular therapy of inflammatory diseases. NF-κB, 
PI3K (Phosphatidylinositol-4,5-bisphosphate 3-kinase) 
and STAT-1 activation have been identified as important 
signalling pathways that enhance the immunosuppressive 
Figure 2: Molecular mechanisms of MSC mediated induction of colon tumour cell initiation, angiogenesis, invasion 
and metastasis. MSCs have been demonstrated to exert direct effects upon tumour cells via secretion of factors like plasminogen activator 
inhibitor (PAI)-1, interleukin (IL)-6 and neuregulin (NRG)1, or by activation of the human epidermal growth factor receptor (HER)2/3 
receptor. The result of this signalling is activation of a number of pathways in the tumour, the net result of which is tumour promotion. 
Activation of HER2/3 leads to an increased invasive and metastatic capacity in the tumour via the phosphatidylinositol-4,5-bisphosphate 
3-kinase (PI3K) and Akt signalling pathway. A similar effect on invasion and metastasis results from MSC-induced increases in Notch1 and 
CD44 signalling in colon tumour cells. Additionally, MSCs can induce phospho-signal transducer and activator of transcription (STAT)3 
signalling in tumour cells which has been described as important in the initiation of tumourigenesis. Finally MSC induced increases in 
hypoxia-inducible factor (HIF)-1α, vascular endothelial growth factor (VEGF) and endothelin (ET)-1 can either directly, or indirectly via 
actions by tumour cells upon healthy endothelial cells, induce tumour angiogenesis, another important factor in increasing the growth and 
progression of tumours both by providing a means for the tumour to travel to distant sites, and delivering nutrients essential for the survival 
of the tumour. 
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capacity of stromal cells [53, 54], however no studies 
have addressed this in the context of tumours. This 
highlights that further work is necessary to better 
understand the mechanisms that control stromal cell 
mediated immunosuppression in the TME with a view 
to manipulating these pathways for therapeutic benefit in 
cancer.
RECRUITMENT OF MSCs TO THE 
TUMOUR MICROENVIRONMENT
Inflammation is the body’s response to tissue 
damage or injury [55, 56]. There is a strong and well 
established link between chronic inflammation and the 
development of colorectal cancer, and this has led many 
researchers to compare the TME to a “wound that does not 
heal” [57, 58]. In this sense, the factors that orchestrate 
recruitment of cells to the TME are likely to be similar to 
that of a wound, to counteract inflammation and promote 
wound healing. While desirable in a wound, this type of 
response is unfavourable in CRC and undoubtedly aids to 
progression of the disease. 
Research on the molecular pathways associated 
with inflammation associated CRC has identified colon 
epithelial cell NF-κB, STAT3 and STAT6 activation with 
the progression of chronic intestinal inflammation to 
overt CRC [58-61]. In colorectal cancer, NF-κB has been 
described as the “critical link” between inflammation and 
cancer, and also found to feature in the wound healing 
process [58, 62, 63]. Research focusing on the recruitment 
of MSCs to tumour cells has identified the importance of 
various signalling molecules in this process, including 
CXCR4, MCP-1 and VCAM-1, all of which are regulated 
by NF-κB [64-72]. Shi et al., found the CXCR4/SDF1 
signalling axis to be of importance in MSC homing to 
the bone marrow in irradiated NOD/SCID mice [68]. 
This was confirmed by Gao et al., who identified SDF1 
to be an important stimulus for MSCs to migrate towards 
tumour conditioned medium [69]. Other important factors 
implicated in this process are MCP-1, the blockade of 
which significantly reduced the migration of MSCs to 
breast tumour xenografts in mice, and VCAM-1 which 
has been shown to enhance MSC migration to glioma 
cells in vitro [70, 71]. With regards specifically to the 
setting of colorectal cancer, a study by Uchibori et al., 
in 2013 confirmed an important role for VCAM-1 in the 
process of migration [72]. In addition to this important 
role for tumour cell NF-κB, recent research has shown that 
stromal cell NF-κB is also has a part to play in colorectal 
tumourigenesis, when a decreased tumour incidence was 
identified following intestinal stromal cell specific deletion 
of IKKβ [37]. In the context of inflammation associated 
cancer and spontaneous CRC, it is likely that there are 
multiple mechanisms involved in MSC recruitment to 
the TME. It is well established that MSCs are recruited 
to the tumour microenvironment and once there, act 
to alter tumour biology. In depth knowledge of how 
tumours regulate the process of MSC recruitment and 
how MSC migration is affected by inflammation in the 
tumour microenvironment is needed. More specifically, 
identification of tumour specific mechanisms that regulate 
MSC migration, and an understanding of how these 
mechanisms can be targeted is essential.
MSCS PROMOTE TUMOURIGENESIS 
IN VIVO
Apart from their proposed role as CAF precursors, 
MSCs have also been shown to be capable of modulating 
colon cancer cell activity through other mechanisms. In 
fact MSCs in CRC have been shown to directly influence 
at least three of the six seminal “Hallmarks of cancer” 
proposed by Hanahan and Weinberg [73], namely evasion 
of apoptosis [46], sustained angiogenesis [46, 74, 75] and 
tissue invasion and metastasis [46, 75, 76].
Numerous mechanisms are responsible for the 
observed effects of MSCs on colon tumour activity. Hogan 
et al., found bone marrow derived MSC (BM-MSC)-
secreted PAI-1 to be responsible for the increases they 
saw in HCT116 and HT29 colon tumour cell migration 
in vitro [76]. Liu et al., found pre-treating BM-MSCs 
with inflammatory cytokines induced VEGF expression 
via HIF-1α signalling in MSCs and resulted in increased 
angiogenesis observed in tumours following C26 colon 
cancer cell and MSC co-injection [74]. Lin et al., showed 
that MSC-secreted IL-6 and Notch1 and CD44 induction 
in HCT116 increased metastatic potential in tumours 
formed following co-injection of HCT116 and colon 
cancer-MSCs in Balb/c nu mice [77]. De Boeck et al., 
found that BM-MSCs increased the invasion, survival 
and tumorigenesis of various colon cancer cell lines in 
vitro through the release of soluble NRG1 and subsequent 
activation of the HER2/HER3-dependent PI3K/Akt 
signalling cascade in colon tumour cells, and that co-
administration of these BM-MSCs with the various cancer 
cell lines in vivo increased the percentage of animals 
presenting with tumours a number of weeks after injection 
[75]. Similarly, Huang et al., found that MSCs enhanced 
angiogenesis and migration of tumours formed in athymic 
nude Balb/c mice following administration of HT29 colon 
cancer cells, and identified IL-6 secretion by MSCs as the 
putative mechanism responsible for these increases [78]. 
Accumulating evidence suggests that MSCs enhance 
various aspects of colon tumour cell biology which 
favours tumour growth, survival and progression (Figure 
2). While this may be the case, the studies referenced 
here are not without limitations. Firstly, as was noted in 
the review by Hogan et al., there is a lack of uniformity 
in much of this work, particularly with regard to the 
variation in the numbers of cells and ratios of MSCs to 
tumour cells being administered in each study, and the 
physiological relevance of the tumour cell:MSC ratios 
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[79]. The physiologically relevant ratio of MSCs present 
in the colorectal cancer microenvironment is likely to be 
crucial in fully assessing the specific role MSCs play in 
the CRC TME and indeed other cancers. Secondly, the 
majority of the preclinical studies in this area rely on 
the use of xenograft models of cancer, namely human 
colon cancer cells, often HT29 or HCT116, being co-
administered with human MSCs, bone marrow-derived or 
otherwise, to a mouse lacking a fully competent immune 
system, commonly athymic nude Balb/c or Swiss nu/nu 
mice. While this model has its advantages and is clearly 
necessary to facilitate the engraftment and outgrowth of 
the administered tumour cells that could otherwise be 
rejected by the host animal, the autologous nature of the 
disease is not accurately represented, and aspects of the 
“anti-tumour-immunity machinery” are absent. These 
immune cell components such as T-cells, macrophages, 
dendritic cells and natural killer cells could, in fact, be 
central players in MSC-mediated tumourigenesis. The 
ability to reliably identify the location and ratio of tumour 
MSCs would facilitate approaches to comprehensively 
investigate their influence on tumour cells and immune 
Figure 3: Outline of the potential immunomodulatory effects of MSCs in the colon tumour microenvironment. MSCs 
have been shown to have potent immunomodulatory effects, acting on components of both the innate and adaptive immune system. In 
terms of innate immunity it has been shown that MSCs can dampen any early immune response that the host system may mount against a 
transformed tumour cell. This dampening of the initial response is due to the ability of the MSCs to decrease the proliferation and activation 
of dendritic cells (DCs) and natural killer (NK) cells, the potential “first responders” of an anti-tumour immune response. Macrophages 
represent another important group of innate immune cells with the potential to exert anti-tumour response, particularly via release of 
pro-inflammatory cytokines from their M1, pro-inflammatory-like phenotype. This effect is also hampered by MSCs which act to induce 
a more M2, anti-inflammatory phenotype in macrophages, thus inhibiting their capacity to clear transformed cells. With regards to the 
adaptive immune compartment, it has been demonstrated that MSCs have differential effects upon different t-cell populations. Evidence 
from the literature shows that release of factors such as transforming growth factor (TGF)-β, hepatocyte growth factor (HGF), indoleamine 
2,3-dioxygenase (IDO) (human), nand nitric oxide (NO) (rodent) from, and induction of B7H1 or PD-L1 expression on MSCs directly 
reduces the proliferation and cytotoxic effects of effector CD4+ and CD8+ T cells, thus inhibiting their tumour-clearing capacity. In contrast, 
signalling by MSCs has been reported to increase the proliferation of regulatory t cells (Tregs), a population which act to suppress the activity 
of other effector t cells. In healthy tissue this supressed auto-immunity and tolerance of “self” is desirable, but in a tumour, where the aim is 
to clear transformed cells, the increased proliferation of Tregs can be detrimental to tumour lysing and clearing by cytotoxic T cells.
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cells in both physiologically relevant models and human 
specimens. 
MSCS AS MEDIATORS OF ANTI-
TUMOUR IMMUNITY
The theory of cancer immunoediting describes the 
ability of the immune system to survey the landscape 
for potential cancerous growths, and to interact with 
tumours and directly alter their immunogenicity [80, 81]. 
According to this theory, the immune system can protect 
the host by recognising immunogenic tumour cells and 
mounting a T-cell mediated response to actively eliminate 
these cells (the “elimination” phase) [82, 83]. The 
corollary of this elimination of immunogenic cells is that 
the outgrowth of other, less immunogenic tumour cells 
may be favoured (the “equilibrium” and “escape” phases) 
[81, 82, 84]. There are undoubtedly numerous mechanisms 
by which tumour cells interact with and avoid clearance 
by the immune system such as insensitivity to interferon 
(IFN)-γ, and alteration in tumour cell MHC class I 
molecules and antigen presentation [85-87]. However, 
evidence now suggests that MSCs may have an important 
role to play in this process. MSCs possess immune 
regulatory functions, and in particular have been shown to 
be immunosuppressive in response to pro-inflammatory 
cytokines or TLR ligation [88-91]. In the colorectal TME, 
where inflammatory signalling is prevalent, it has been 
suggested that MSCs interact with immune cells, resulting 
in dampening of anti-tumour responses and thereby 
promoting tumorigenesis [92-94]. Numerous mechanisms 
have implicated in how MSCs modulate the immune 
components of the TME. Quite often the focus has been on 
MSC-T-cell interactions, but influences on other immune 
cell subpopulations such as macrophages and dendritic 
cells (DCs) have also been identified. In the context of the 
TME, MSC influences on the phenotype of these immune 
cells will dramatically affect tumour progression and a 
thus a better understanding of the precise mechanisms 
involved is critical to the development of more efficacious 
immunotherapies (Figure 3).
INFLUENCE OF MSCs ON THE INNATE 
IMMUNE SYSTEM IN THE TUMOUR 
MICROENVIRONMENT
As noted by Lamagna et al., macrophages could 
be considered the first line of defence against tumours 
given that they colonise rapidly and secrete cytokines 
to activate other innate immune components such as 
dendritic cells (DCs) and natural killer cells (NK cells) 
[95]. Additionally, macrophages have been shown to be 
capable of phagocytosis of dead tumour cells and cross-
presention of tumour antigen to CD8+ T cells [96] 
MSC-induced polarisation of macrophages 
towards an M2 phenotype
Evidence shows that MSCs can exert their tumour 
promoting effects by interacting with macrophages in the 
TME [97, 98]. Macrophages can be polarised to an M1 
phenotype which secrete reactive oxygen and nitrogen 
species and inflammatory cytokines, or an M2 phenotype 
which are involved in the suppression of inflammation and 
tissue remodelling [99]. Tumour-associated macrophages 
(TAMs) have been found to be of the M2 phenotype 
which, in the context of the tumour microenvironment, 
results in dampening of anti-tumour immune responses 
[97, 98]. It has been shown that MSCs can polarise 
macrophages towards this “anti-inflammatory” M2 
phenotype, characterised by IL-10 production and 
decreased iNOS and IL-12 expression [60, 100], and 
this likely represents another important mechanism by 
which MSCs aid tumours in evading immune clearance. 
Ren et al., showed that tumour-educated MSCs greatly 
enhanced tumour growth, and that this enhancement 
could be ameliorated by monocyte/macrophage depletion 
[101]. They also showed that these tumour-educated 
MSCs expressed high levels of CCR2, the major cytokine 
involved in monocyte chemotaxis [102]. Although these 
studies demonstrate the ability of MSCs to induce and 
M2 phenotype, the factors responsible for this induction 
remain elusive. Factors implicated in this switching 
include soluble mediators such as CCR2, IL-6 and GM-
CSF [101, 103]. M2-like macrophages could be important 
targets in the context of developing novel therapeutics or 
adjuncts to improve the efficacy of those currently used 
[60, 97, 104]. However, macrophages perform several 
essential functions throughout the body and so caution 
must be taken in therapeutically targeting such a cell. 
Identification of factors released by MSCs in the tumour 
microenvironment that are responsible for inducing an M2 
macrophage phenotype could be even more advantageous 
for the development of cancer immunotherapy, the 
effect of which is largely dependent on macrophage 
effector functions, including antibody dependent cellular 
cytotoxicity and phagocytosis.
MSCs induce suppression and altered function 
in dendritic cells, natural killer cells, neutrophils 
and myeloid derived suppressor cells
Although most studies looking at the importance 
of the immune cell components to tumour growth focus 
elsewhere, there is a body of evidence to support the 
hypothesis that dendritic cells (DCs) and natural killer 
(NK) cells also have an important role to play in the anti-
tumour immune response [105-107]. Furthermore, DCs 
and NK cells are also known important components of 
the colorectal tumour microenvironment [28]. Tumour 
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cell antigens, released either in the form of dying tumour 
cells or soluble antigen, can be endocytosed by dendritic 
cells in the TME. Dendritic cells undergo maturation and 
migrate to secondary lymphoid organs where they can 
present processed tumor antigens as peptides bound to 
class I and II MHC molecules to prime effector CD8+ and 
helper CD4+ T cells, respectively [108]
Despite the lack of studies related directly to the 
effects of MSCs on DCs and NK cell effector functions 
in the tumour microenvironment, it is likely their effects 
are similar to those described in other tissues. Aggarwal 
et al., showed using co-cultures that MSCs can suppress 
both proliferation and cytokine secretion, not only by 
T-cells, but also by DCs, and NK cells, and that these 
effects can be reversed by PGE2 synthesis inhibitors, 
suggesting PGE2 may be also be important in MSC-
induced immunosuppression [109]. This is a potentially 
important finding in the context of CRC. Non-steroidal 
anti-inflammatory drugs (NSAIDS) have been shown to 
have a protective effect against the development of CRC 
[110-112] owing to their ability to inhibit cyclooxygenase 
(COX)-2, the enzyme that is responsible for the production 
Figure 4: Tumour- and MSC-derived exosomes as potential mediators of colon tumour cell proliferation, migration, 
angiogenesis and modulation of anti-tumour immune response. Experiments involving transwell systems and conditioned 
medium have shown us that soluble factors released by MSCs can promote all aspects of tumourigenesis including tumour cell proliferation, 
migration and angiogenesis. Interestingly, more recent experiments involving the treatment of tumour cells with exosomes isolated from 
MSCs have produced similar results. Exosomes are vesicles released by a cell which are between 30 and 100nm in diameter, making them 
small enough for easy uptake by target cells. Exosomes released from a cell can contain many different components including proteins, 
lipids, RNA and miRNA. It is for these reasons that exosomes could represent a key under-explored aspect of tumour-MSC interactions. 
In addition to MSC derived exosome effects on tumour cells, it has now also been shown that exosomes derived from tumour cells can 
alter the biology of MSCs, and indeed immune cell components. Tumour derived exosomes can express FasL and TNF-related apoptosis 
inducing ligand (TRAIL), thus inhibiting macrophage differentiation and inducing t-cell apoptosis. In terms of the effects of tumour 
released exosomes on MSCs, data to date is limited. Early evidence does show however, that MSCs secrete (IL)-6, chemokine ligand 
(CXCL)-1 and C-C chemokine receptor (CCR)-2 upon treatment with tumour derived exosomes, all factors which have been implicated in 
cancer progression, metastasis and poor prognosis.
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of PGE2 from arachidonic acid [113, 114]. Spaggiari et al., 
showed that MSCs inhibited both the proliferation and 
effector functions of NK cells, and the maturation and 
effector functions of DCs, and that these effects were, as in 
the case of T-cells, mediated by IDO and PGE2, molecules 
released by MSCs in response to inflammatory signals that 
are prevalent in the colon TME [115, 116].
Myeloid-derived-suppressor cells (MDSCs) are 
another family of immune cells derived from myeloid 
progenitors and shown in humans to express varying 
levels of CD11b, CD14, CD15 and CD33 [117, 118]. 
MDSCs have an immature phenotype and the potential 
to suppress T cell responses via expression of arginase 1, 
inducible NOS, TGF-β, IL-10, COX2 or the induction of 
Tregs [117, 119] . Research has shown that these MDSCs 
can affect tumour growth and progression in a number 
of ways, including protecting the tumour from immune 
mediated clearance by their secretion of NOS, TGF-β, IL-
10, PGE2 [118, 119] 
Factors responsible for the accumulation of MDSCs 
in the tumour microenvironment include GM-CSF, 
G-CSF, M-CSF, all of which are produced by MSCs, 
suggesting the potential role of MSCs in recruitment and 
accumulation of MDSCs in the tumour [118, 119]
Evidence suggests that tumour-derived MSCs 
have an even more pronounced effect on MDSCs, as 
demonstrated by the induced expansion of MDSCs in 
vitro when in co-culture with tumour derived MSCs. 
Furthermore, these expanded MDSCs were functionally 
active and shown to suppress allogeneic T cell 
proliferation, demonstrating the potential to hamper an 
anti-tumour immune response [118, 120, 121].
Figure 5: Dual role of MSC in the prevention of inflammation induced colon cancer development and promotion of 
colon cancer metastasis. Although the vast majority of the evidence points to a tumour promoting role for MSCs, there is some evidence 
to the contrary. However, this anti-tumour effect appears to be specific to the very early stages of tumour development. Throughout the 
course of a chronic inflammatory condition like inflammatory bowel disease (IBD) the epithelium becomes inflamed and damaged, leading 
to the production of factors such as nuclear factor kappa B (NF-κB), signal transducer and activator of transcription (STAT) 3 and STAT6, 
all of which are potentially tumourigenic. It appears that administration of MSCs at this very early stage can have a tumour inhibiting effect 
by decreasing interleukin (IL)-6 and phosphoSTAT3 signalling and reducing DNA damage. However, once this early stage has passed, 
MSCs recruited to the tumour by factors such as nuclear factor (NF)-κB, chemokine receptor type 4 (CXCR4), stromal cell derived factor 
(SDF)1, monocyte chemotactic protein (MCP)-1 and vascular cell adhesion molecule (VCAM)-1 serve only to promote tumourigenesis via 
the mechanisms mentioned throughout this review, namely differentiation to cancer-associated fibroblasts (CAFs), promotion of tumour 
growth, invasion, metastasis and angiogenesis and the dampening of anti-tumour immunity.
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Finally, a limited amount of data exists 
demonstrating a detrimental role for neutrophils in the 
TME in terms of promoting tumorigenesis and inhibiting 
apoptosis [122, 123]. Neutrophils normally play an 
important role in killing invading microorganisms and 
although scant, evidence suggests that MSCs have the 
capacity to interact with this cell type. It has in fact been 
shown that MSCs can protect neutrophils from apoptosis 
and that neutrophils activated by tumour-resident MSCs 
can promote the differentiation of normal MSCs into 
CAFs, thus contributing to tumour promoting role [124-
126]
This data demonstrates that MSCs in the TME have 
the capacity to suppress effector functions of numerous 
innate immune cells which act as a first-line defence in 
detecting transformed cells. Furthermore, this appears to 
be orchestrated via release of soluble factors, namely IDO 
and PGE2 by the MSCs, meaning that these effects can be 
functional even in the absence of cell contact with MSCs. 
Elucidation of these complex interactions is vital in order 
to re-activate the host innate immune system to allow the 
generation of an effective anti-tumour immune response. 
INFLUENCE OF MCSS ON COMPONENTS 
OF THE ADAPTIVE IMMUNE SYSTEM
MSC-mediated effects on T-cells
Much of the evidence for MSC-mediated 
immunomodulation has focused on the effects of MSCs 
on the proliferation and/or effector functions of T-cells. 
Di Nicola et al., found that MSCs could inhibit the 
proliferation of T cells that had been stimulated by 
allogeneic peripheral blood lymphocytes (PBLs), dendritic 
cells (DCs) or phytohemagglutinin (PHA), and that this 
inhibition was contact-independent and could be reversed 
using antibodies against TGF-β1 and HGF, suggesting 
an important role for these cytokines in MSC mediated 
immunomodulation [89]. Similar work by Meisel et 
al., identified indoleamine 2,3-dioxygenase (IDO) as 
important in MSC-mediated T-cell suppression, a finding 
which has been backed up by other separate studies [127, 
128]. These findings are complicated by the fact that the 
results are only applicable to MSCs isolated from humans 
and monkeys [129]. When looking at rodent MSCs, IDO 
appears dispensable, with nitric oxide (NO) found to be 
responsible for T-cell suppression in this setting [88, 129]. 
More recently, another, IDO-independent mechanism for 
MSC-mediated immunosuppression has been identified. 
Chinnadurai et al., found that while blocking IDO negated 
the suppressive effect of MSCs on T-cell proliferation, 
it did not reverse the suppressive effects of MSCs on 
T-cell function as measured by IFN-γ secretion. Instead, 
the B7H1 (PD-L1) and B7DC (PD-L2) /PD1 pathways 
was implicated in the ability of MSCs to suppress T-cell 
function [130].
While there are clearly numerous suggested 
mechanisms responsible for this suppressive effect, 
there is definitive evidence to show that MSCs inhibit 
T-cell proliferation, but only following T-cell activation, 
proliferation, and subsequent cytokine production, in 
particular IFN-γ [88, 128]. T-cell stimulation is a common 
feature of an inflammatory TME [131]. Furthermore, 
studies indicate that MSCs are more immunosuppressive 
when pre-treated with inflammatory cytokines, and can 
home to sites of inflammation, such as that of the TME 
[132, 133]. This implies a role for MSCs in migrating 
to the TME [134] and aiding tumours avoid clearance 
by interacting with and modulating the host anti-tumour 
immunity. 
Djouad et al., provided some of the earliest evidence 
to link this MSC-induced immunosuppression to enhanced 
tumour growth [135]. They found the murine C3 MSCs 
cell line to be immunosuppressive in vitro, and when 
injected with B16 melanoma cells in allogeneic CH3 mice, 
these MSCs induced greater tumour formation compared 
to the control groups of MSCs or B16 cells alone. This 
result was observed regardless of whether the MSCs and 
B16 cells were co-injected or injected at separate sites, 
and for numerous ratios of MSC:B16 up to 1:100, which is 
important in the context of physiological relevance..
More mechanistic insights came from Patel et 
al., who found that MSCs protected breast cancer cells 
from immune clearance by increasing TGF-β production 
which caused an upregulation in the production of Tregs 
cells [92]. Ljujic et al., found a similar upregulation of 
Tregs along with a decrease in the cytotoxic capacity of 
CD8+ T-cells and NK cells in mice that had been co-
administered 4T1 mammary carcinoma cells and hMSCs, 
and these effects coincided with an increase in tumour 
growth and metastasis. Mechanistically it was found that 
the administration of hMSCs caused significant increases 
in serum levels of TGF-β, IL-4 and IL-10 and a reduced 
level of IFN-γ in tumour bearing mice, findings which are 
consistent with MSCs affecting NK and T-cell activity 
and polarising T-cells away from a Th1 phenotype [92, 
136]. Han et al., showed that co-injection of MSCs with 
B16 cells increased tumour growth over that of B16 cells 
alone, and that a further increase in growth occurred when 
the MSCs were pre-treated with IFN-γ and TNF-α. NO 
production and T-cell suppression was the mechanism 
cited here as being responsible for the increased growth 
of tumour cells, owing to the observation that iNOS 
inhibition reversed the MSC-mediated enhanced tumour 
growth. As mentioned, however, where MSC NO mediates 
an immunosuppressive effect in rodents, IDO appears to 
be the human equivalent [129, 132]. This discrepancy was 
overcome in a set of elegant experiments by Ling et al., 
who “humanised” murine MSCs by transfecting iNOS-
/- mouse MSCs with the human IDO gene, leading to 
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constitutive IDO expression in these cells [94]. In addition, 
they engineered the cells to inducibly express human IDO 
expression under the control of the promoter of the mouse 
iNOS gene, thus more accurately resembling the human 
in vivo situation whereby IDO expression is upregulated 
in response to inflammatory signalling. This study 
concluded that IDO produced by MSCs was responsible 
for the enhanced tumour growth and that suppression 
of CD8+ cells was critical for this effect [94]. Effector 
T-cells have a central role in orchestrating the anti-tumour 
immune response [137]. Identification of tumour induced 
mechanisms of MSC-mediated immunomodulation that 
inhibit T-cell proliferation, differentiation and function will 
enable the development of more targeted and efficacious 
immunotherapies, thus reducing reliance on cytotoxic 
chemotherapeutics and leading to more favourable 
outcomes for patients.
In the context of colon cancer Liu et al., in 2011, 
treated murine MSCs with IFN-γ and/or TNF-α and co-
injected these cells with murine C26 colon cancer cells into 
a Balb/c mouse model [74]. Although this study focused 
primarily on the pro-angiogenic role of these MSCs, it 
could be that these cells were also exerting suppressive 
effects on the immune system. This model, unlike many 
of the other cited here, is a syngeneic model where all cells 
used are of Balb/c origin, and so is particularly suitable for 
studying tumour-immune interactions. The authors found 
that cytokine treated MSCs were more potent promoters of 
angiogenesis, and attributed this effect to increased VEGF 
expression in MSCs as a result of HIF-1α signalling. 
While obviously angiogenic, VEGF has more recently 
been shown to be immunosuppressive, and so it could 
be that the MSCs administered in this study are having 
more than one effect on the tumour cells and actually 
aiding their avoidance of immune clearance as well as 
promoting angiogenesis [138, 139]. Another role for 
VEGF in tumour progression has also been noted - namely 
macrophage recruitment to the tumour microenvironment 
and the subsequent development of an immunosuppressive 
tumour-associated macrophage (TAM) phenotype [139].
What all this data demonstrates is that MSCs 
play a central role in maintaining homeostasis by 
modulating the function of innate and adaptive immune 
cells. Furthermore, it has been shown that MSCs can 
behave as ‘non-professional antigen presenting cells’ 
as demonstrated by their ability to sense bacteria via 
TLRs/NLRs, their expression of MHC class II and their 
aforementioned ability to alter T cell function [15, 140]. 
Evidence in support of this includes, IFN-γ induction of 
MHC-I and MHC-II expression and the ability to present 
soluble exogenous antigen leading to the activation or 
anergy of CD8+ and CD4+ T cells. [141-143]. Furthermore, 
CD90+ intestinal stromal cells have been shown to be 
capable of bacteria uptake and phagocytosis [144]. 
This has provoked the question of whether MSCs are 
immune cells. A recent review by Hoogduijn addresses 
this question in detail [50] , with the conclusion that 
MSCs, though immunomodulatory, are not in fact 
immune cells. In spite of this, the data presented does 
highlight some interesting idiosyncrasies related to MSC 
behaviour that does suggest characteristic “immune-like” 
functions, although to a different extent than professional 
immune cells. Hoogduijn points out that an immune 
cell is classified as a cell that protects the host against 
pathogens and removes debris or diseased cells. To date, 
data demonstrating these functions in MSC is limited or 
even absent. At present, in the tumour microenvironment, 
MSCs act as the “sensors and switchers of inflammation” 
described by Bernardo and Fibbe in the sense that they 
detect altered immune activity, respond to it, and as 
outlined above, interact with and influence the behaviour 
of components of the innate and adaptive immune system 
[24], This is an attempt, presumably, to protect the host 
from excessive inflammation rather than a pathogenic 
threat. However, little is known about the other immune 
cell-like functions of MSCs, and even less so the influence 
of tumour conditioning on these processes. Can MSCs 
phagocytose transformed or apoptotic tumour cells? Can 
they induce tolerance by presenting tumour antigen as 
“self”? Is it possible even that MSCs could be polarised 
by tumour conditioning to a pro- or anti-tumorigenic 
phenotype, as is the case for M1/M2 type macrophages. 
These questions require much investigation before we can 
fully understand the immunomodulatory capacity of MSCs 
in maintaining tissue homeostasis and more importantly, 
their role in dictating the anti-tumour immune response in 
the colon cancer microenvironment. 
EMERGING CONCEPTS - COULD 
EXOSOMES PROVIDE A KEY MISSING 
LINK?
While evidence varies as to the precise mechanisms, 
it is clear that the interactions between MSCs and 
components of the TME have profound effects on tumour 
growth and metastasis. Data suggests that these effects are 
not dependent on direct contact between tumour cells and 
MSCs or between MSCs and immune cells. Several MSC 
derived soluble mediators have been proposed as crirical 
for this pro-tumourigenic effect, but there is not yet a 
consensus as to which factors are key players, which play 
supporting roles, and which ones are dispensable. It seems 
likely that tumour microenvironment MSC mediated 
effects require the concerted actions of numerous secreted 
factors, each with its own important role. The idea that 
multiple signalling mechanisms are likely responsible for 
cell-cell communication has gained momentum of late - 
namely in the study of extracellular vesicles (EVs), and in 
particular, exosomes.
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Exosomes are vesicles released by a cell which 
are between 30 and 100nm in diameter, and can be 
identified by their unique protein and lipid composition, 
“saucer-like” morphology and expression of exosomal 
markers including TSG101 and CD63 [145, 146]. 
Exosomes released from a cell can contain many different 
components including proteins, lipids, RNA and miRNA 
[147-150]. Emerging evidence suggests that these vesicles 
could be, at least in part, responsible for some of the 
altered characteristics of MSCs found in the TME, and 
also for some of the tumour promoting effects exerted 
upon tumour cells by MSCs. For example, Haga et al., 
found that exposure to tumour cell EVs caused MSCs 
to express α-SMA, a marker for CAFs, and to secrete 
CXCL-1, CCL2 and IL-6, factors known to be involved in 
cancer progression, metastasis and poor prognosis [151-
153]. Furthermore, the conditioned medium from MSCs 
exposed to tumour EVs caused a subsequent increase 
in tumour cell proliferation and migration [151]. The 
importance of tumour cell exosomes was evident when 
Webber et al., noted that exosomes from tumour cells 
could induce normal prostate stroma to become disease-
like in phenotype and function as measured by secretion 
of soluble factors, angiogenic potential and the ability 
to promote tumour growth using samples isolated from 
patients with prostate cancer [154]. 
In addition to exerting direct effects on MSCs, 
tumour-derived exosomes have also been shown to be 
capable of modulating the various components of the 
immune system. With regard specifically to CRC, it has 
been observed that exosomes secreted from colorectal 
tumour cells express FasL and TRAIL, thus inducing 
T-cell apoptosis [155]. Furthermore, it has been shown 
that colorectal tumour-derived microvesicles impair 
monocyte differentiation into dendritic cells and those 
monocytes that do differentiate in the presence of tumour 
cell microvesicles exerted a suppressive effect on T-cell 
activity [156].There is also evidence to suggest that 
exosomes released from MCSs can enhance the growth 
and angiogenesis of tumours in vivo, possibly even to 
the same extent as MSCs themselves [157] and that 
these MSC-released exosomes can also induce a state of 
dormancy in tumour cells that favours their survival until 
conditions for re-growth and metastasis are optimal [158] 
(Figure 4). These observed effects allude to a potentially 
vital role for both tumour- and MSC-derived exosomes in 
the process of cancer progression, particularly due to their 
small size and apparent ease of uptake into recipient cells. 
Therefore, the mediators of exosome uptake may represent 
novel targets for therapeutic manipulation [159], although 
a good deal more investigation is needed in this area.
MSCs  IN THE TUMOUR 
MICROENVIRONMENT - A DOUBLE-
EDGED SWORD?
A small number of recent publications add a further 
level of complexity to the colorectal cancer-MSCs 
narrative. Studies by Chen et al. and Nasumo et al., looked 
at the impact of MSCs on the development of colon cancer 
following treatment with azoxymethane (AOM) alone, 
or in combination with dextran sulphate sodium (DSS) 
[160, 161]. The DSS-AOM model is a well-accepted 
model of inflammation-associated colorectal cancer 
whereby DSS provides the inflammatory insult and is 
followed by the carcinogen AOM to induce colon tumour 
formation [162]. In each of these studies, administration 
of MSCs at different stages of the DSS-AOM protocol 
resulted in an inhibition of tumourigenesis. Chen et al. 
attributed this reduction to decreased IL-6 and pSTAT3 
signalling in colon cells, whereas Nasuno et al., found 
MSCs prevented initiating cells from sustaining DNA 
insults and induced G1 arrest in initiated cells via TGF-β 
signalling [160, 161]. Undoubtedly these two studies 
bring to light some interesting aspects of MSC-colorectal 
cancer interactions, and raise the question of how MSCs 
can be anti-tumourigenic in the setting of healthy tissue 
exposed to a carcinogenic insult, but be pro-tumourigenic 
once the early tumour initiation phase has passed. Could 
it be that the MSCs, being immunosuppressive, dampen 
any inflammatory response that so often leads to tumour 
development in the colon [163, 164], but that excess 
anti-inflammatory signalling hinders the tumour-immune 
response? These models could represent the “elimination” 
phase of the tumour-immune response mentioned earlier. 
In the clinical setting colorectal tumours don’t usually 
develop quickly or in response to an acute chemical 
insult as provided by the DSS-AOM models, and perhaps 
MSCs are not recruited to the site until later on in the 
process in contrast to these studies where MSCs were 
administered in high numbers very early on in the process 
of tumour development (Figure 5). Further studies refining 
the precise contributions of MSCs to tumourigenesis 
at each stage of the cancer development process is 
vital, particularly when it is noted that MSCs are being 
investigated for their potential to therapeutically modulate 
inflammatory diseases of the intestine, including Crohn’s 
disease [165]. These data cited here could also suggest 
that the role of MSCs in the tumour microenvironment is 
tumour and context specific, highlighting the urgent need 
for standardised models.
More recent research has aimed to harness the 
tumour-homing property of MSCs to deliver cancer-
specific drug or gene therapy to patients, with some 
positive outcomes being observed [166-170]. This 
concept arose from MSCs remarkable ability to ‘home’ 
to tumours. In fact the first clinical trial using MSCs as 
an anti-cancer therapy is currently underway in Germany 
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(eudract_number:2012-003741-15). Although no results 
have been published to date, this is yet another interesting 
facet of the MSC-tumour story where the immunological 
consequences of MSCs may have more important effects. 
The rationale behind this study is to engineer a patient’s 
own MSCs to express therapeutic gene of interest and 
make use of the tumour-homing capacity of MSCs so as 
to allow for IV administration of the engineered MSCs 
[171] These MSCs will, however, also be transfected with 
a replication-incompetent and self-inactivating vector 
system so as to avoid any potential adverse effects of a 
bolus of MSCs being recruited to the TME, one of which 
effects would presumably include immunosuppression 
and potential tumour-immune evasion. [171]. This trial 
is based upon a number of pre-clinical studies showing 
potential efficacy in inhibiting tumour growth or metastasis 
of MSCs engineered to express anti-cancer therapies 
such as CX3CL-1, TRAIL and IFN-β [169, 172-174]. 
However, as with all pre-clinical studies, these results 
were obtained over a short period of time in animals with 
exogenously administered tumours displaying a much 
accelerated growth rate compared to that of patients. For 
these reasons, and the fact that the follow up periods in 
these studies were short, and thus limited the analysis of 
long term immunological consequences, these results must 
be interpreted with caution.
A final important aspect of CRC-MSC interactions 
is the potential impact that these cells could have on 
colorectal cancer therapy. Recent research has highlighted 
the ability of MSCs to contribute to resistance to 
chemotherapeutics in both haematological malignancies 
and solid tumours [175-177]. In CRC 5-Fluorouracil (5-
FU) is one of the first-line therapies for metastatic disease 
[178]. However, it has now been shown that a population 
of bone-marrow MSCs exist that are both potently 
immunosuppressive and 5-FU resistant, a dangerous 
combination in the context of CRC chemotherapy [179]. 
Difficulties also arise with the use of radiotherapy [180]. 
MSCs have been shown to be radio-resistant [181, 
182] and so could withstand such therapy and retain 
their tumour-conditioned phenotype, thus potentially 
contributing to disease relapse. 
Table 2: Key under-explored areas of research into the effects exerted by stromal cells in the tumour microenvironment.
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FUTURE PERSPECTIVES
Following review of recent publications as detailed 
here, it is clear that the impact of tumour-educated 
MSCs on the immune system plays a significant role 
in MSC-mediated tumour promotion. The putative 
mechanisms of this element of assisted immune escape 
are elucidated, albeit with varied results as to particular 
mechanisms responsible. Nevertheless, key areas in 
which gaps remain in our knowledge include the precise 
mechanisms by which tumours recruit MSCs, or activate 
tissue resident MSCs, the identification of specific 
markers to reliably identify and quantify MSCs in the 
tumour microenvironment, the precise mechanisms by 
which tumour-educated MSCs influence immune cell 
components and the mechanism of release, uptake and 
consequent signalling induced by extracellular vesicles by 
both MSCs and tumour cells, not to mention determining 
the actual content of these vesicles.
Furthermore, as was noted by Khong and Restifo 
in their review of tumour-escape phenotypes in 2002 
[183], all of these results must be interpreted with caution. 
These studies are carried out in mice that have been 
administered a high dose of potent, fast growing, often 
allogeneic, tumour cells, and very often a similarly high 
dose of MSCs, and so the results from these studies cannot 
be interpreted as accurately representing what is often 
the very slow and poorly understood process of cancer 
development in humans. These words of caution point 
to an ever increasing need for more relevant pre-clinical 
models of spontaneous tumour development in future 
studies. Together, with more sensitive imaging systems, 
the role of MSCs in spontaneous tumour development, will 
certainly unfold in the near future. Until these questions 
are answered and data is available from human specimens, 
the use of MSCs as a cellular therapy for patients with 
a genetic predisposition or those at an inherent increased 
risk for tumour development must be translated with great 
caution. Finally, to date, no therapies routinely used in 
colorectal cancer treatment specifically target stromal cell 
mediated immunomodulation. A better understanding of 
the albeit complex interactions underpinning these effects 
and a broadening of our understanding of how to identify 
these cells and characterise their interactions with other 
components of the TME will undoubtedly lead to the 
development of more targeted and efficacious anti-cancer 
therapeutics.
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